Trial Outcomes & Findings for A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (NCT NCT03337698)

Last Updated: 2026-05-12

Results Overview

OR was defined as a complete response (CR) or partial response (PR) on two consecutive occasions, ≥4 weeks apart, during Stage 1 as determined by the investigator using RECIST v.1.1. Objective response rate (ORR) was defined as the percentage of participants with OR. CR was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD, in the absence of CR. 95% confidence intervals (CI) for rates were constructed using Clopper-Pearson method. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2 (S1C2): Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

314 participants

Primary outcome timeframe

Up to 50.4 months

Results posted on

2026-05-12

Participant Flow

A total of 314 participants with metastatic non-small cell lung cancer (NSCLC) took part in the study from 27 Dec 2017 to 25 Nov 2025. The study had 2 cohorts: Cohort 1: participants with no prior systemic therapy for metastatic NSCLC \& Cohort 2: participants with 1 prior line of systemic therapy for NSCLC. Multiple combination therapies were compared against common control(s) in Cohorts 1 and 2.

Eligible participants were assigned to 1 of several treatment arms in Stage 1. Participants with PD, loss of clinical benefit, or unacceptable toxicity in Stage 1 were eligible for a different treatment combination in Stage 2. Participants in Stage 1 who did not enter Stage 2 \& those who completed Stage 2 treatment entered the long-term survival follow-up. Results include only those cohorts that enrolled participants; planned cohorts that were never opened for enrollment are not presented.

Participant milestones

Participant milestones
Measure	Stage 1 Cohort 1: Control (Atezolizumab) Participants received atezolizumab 1200 milligrams (mg), intravenous (IV) infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib Participants received cobimetinib 60 mg, orally (PO), once daily (QD) on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cibisatamab (CEA-TCB) Participants received atezolizumab 1200 mg, IV on Day 1 and carcinoembryonic antigen - T-cell bispecific antibody \[CEA-TCB\] 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until disease progression (PD), loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Control (Docetaxel) Participants received docetaxel 75 milligrams per square meter (mg/m\^2), IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 Participants received CPI-444 100 mg, PO, twice daily (BID), on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Idasanutlin + Docetaxel Participants received idasanutlin 150 mg, PO, QD on Days 1-5 of each cycle and docetaxel 50 mg/m\^2, IV infusion on Days 1 and 15 of each cycle until PD or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 milligrams per kilogram (mg/kg), IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Sacituzumab Govitecan (SG) Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin area under the curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stage 1 STARTED	3	5	1	1	66	15	1	16	18	31	1	41	45	30	32	8	0	0	0
Stage 1 Safety-evaluable Population	3	5	1	1	61	15	1	15	16	30	0	40	43	30	31	8	0	0	0
Long-term Survival Follow-up STARTED	1	4	0	1	36	9	1	9	11	20	0	26	28	20	30	5	2	28	19
Stage 1 COMPLETED	1	5	1	1	52	10	1	12	13	29	0	37	34	28	31	7	0	0	0
Stage 1 NOT COMPLETED	2	0	0	0	14	5	0	4	5	2	1	4	11	2	1	1	0	0	0
Stage 2 STARTED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	33	22
Stage 2 Safety-evaluable Population	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	32	20
Stage 2 COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	28	19
Stage 2 NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	3
Long-term Survival Follow-up COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long-term Survival Follow-up NOT COMPLETED	1	4	0	1	36	9	1	9	11	20	0	26	28	20	30	5	2	28	19

Reasons for withdrawal

Reasons for withdrawal
Measure	Stage 1 Cohort 1: Control (Atezolizumab) Participants received atezolizumab 1200 milligrams (mg), intravenous (IV) infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib Participants received cobimetinib 60 mg, orally (PO), once daily (QD) on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until disease progression (PD), loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Control (Docetaxel) Participants received docetaxel 75 milligrams per square meter (mg/m\^2), IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 Participants received CPI-444 100 mg, PO, twice daily (BID), on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Idasanutlin + Docetaxel Participants received idasanutlin 150 mg, PO, QD on Days 1-5 of each cycle and docetaxel 50 mg/m\^2, IV infusion on Days 1 and 15 of each cycle until PD or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 milligrams per kilogram (mg/kg), IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Sacituzumab Govitecan (SG) Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin area under the curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stage 1 Progressive Disease	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0
Stage 1 Protocol Violation	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Stage 1 Physician Decision	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Stage 1 Death	2	0	0	4	2	0	3	2	0	0	3	4	1	0	1	0	0	0
Stage 1 Withdrawal by Subject	0	0	0	10	2	0	0	3	1	1	0	1	0	1	0	0	0	0
Stage 1 Study Terminated by Sponsor	0	0	0	0	0	0	0	0	0	0	1	5	1	0	0	0	0	0
Stage 2 Study Terminated by Sponsor	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Stage 2 Death	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	2
Long-term Survival Follow-up Arm Terminated by Sponsor	0	0	0	0	0	0	1	2	3	0	0	0	0	0	0	0	0	0
Long-term Survival Follow-up Reason not Specified	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	1
Long-term Survival Follow-up Study Terminated by Sponsor	0	0	0	1	0	0	0	0	0	0	4	5	0	0	3	0	2	0
Long-term Survival Follow-up Withdrawal by Subject	0	1	0	6	2	0	2	1	3	0	2	2	1	4	0	1	0	0
Long-term Survival Follow-up Lost to Follow-up	0	0	0	0	0	0	0	0	0	0	1	2	1	1	0	0	2	1
Long-term Survival Follow-up Death	1	3	1	29	7	1	6	8	14	0	19	17	18	25	2	0	24	17

Baseline Characteristics

Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 Participants Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Control (Docetaxel) n=66 Participants Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=16 Participants Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=18 Participants Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=31 Participants Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Idasanutlin + Docetaxel n=1 Participants Participants received idasanutlin 150 mg, PO, QD on Days 1-5 of each cycle and docetaxel 50 mg/m\^2, IV infusion on Days 1 and 15 of each cycle until PD or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=41 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=45 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 Participants Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=32 Participants Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 Participants Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab n=2 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab n=33 Participants Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin n=22 Participants Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Total n=371 Participants Total of all reporting groups
Age, Categorical Stage 1 · <=18 years	0 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	0 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Age, Categorical Stage 1 · Between 18 and 65 years	0 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	35 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	13 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	11 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	8 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	16 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	23 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	17 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	13 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	9 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	6 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	154 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Age, Categorical Stage 1 · >=65 years	3 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	3 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	31 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	5 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	10 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	15 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	18 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	28 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	17 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	23 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	160 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Age, Categorical Stage 2 · <=18 years	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Age, Categorical Stage 2 · Between 18 and 65 years	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	20 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	12 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	32 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Age, Categorical Stage 2 · >=65 years	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	13 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	10 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	25 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Sex: Female, Male Stage 1 · Female	1 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	18 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	5 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	7 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	6 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	8 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	10 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	11 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	8 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	9 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	86 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Sex: Female, Male Stage 1 · Male	2 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	4 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	48 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	10 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	9 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	12 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	23 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	31 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	34 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	22 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	23 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	7 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	228 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Sex: Female, Male Stage 2 · Female	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	9 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	6 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	15 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Sex: Female, Male Stage 2 · Male	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	24 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	16 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	42 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Ethnicity (NIH/OMB) Stage 1 · Hispanic or Latino	0 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	5 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Ethnicity (NIH/OMB) Stage 1 · Not Hispanic or Latino	3 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	5 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	50 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	14 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	15 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	13 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	19 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	27 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	31 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	21 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	20 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	6 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	228 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Ethnicity (NIH/OMB) Stage 1 · Unknown or Not Reported	0 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	14 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	5 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	12 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	13 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	14 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	7 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	12 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	81 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Ethnicity (NIH/OMB) Stage 2 · Hispanic or Latino	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	3 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Ethnicity (NIH/OMB) Stage 2 · Not Hispanic or Latino	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	22 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	16 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	40 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Ethnicity (NIH/OMB) Stage 2 · Unknown or Not Reported	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	10 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	4 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	14 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 1 · American Indian or Alaska Native	0 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	1 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 1 · Asian	1 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	3 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	15 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	8 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	4 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	7 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	5 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	14 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	5 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	9 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	3 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	77 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 1 · Native Hawaiian or Other Pacific Islander	0 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	0 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 1 · Black or African American	0 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	2 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 1 · White	2 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	38 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	5 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	9 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	11 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	14 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	27 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	18 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	19 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	11 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	3 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	162 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 1 · More than one race	0 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	0 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 1 · Unknown or Not Reported	0 Participants n=3 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=5 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	13 Participants n=66 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=15 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=16 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	5 Participants n=18 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	10 Participants n=31 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=1 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	9 Participants n=41 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	13 Participants n=45 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	6 Participants n=30 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	12 Participants n=32 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=8 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	—	—	—	72 Participants n=314 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 2 · American Indian or Alaska Native	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 2 · Asian	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	2 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 2 · Native Hawaiian or Other Pacific Islander	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 2 · Black or African American	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	1 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 2 · White	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	24 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	18 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	43 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 2 · More than one race	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	0 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.
Race (NIH/OMB) Stage 2 · Unknown or Not Reported	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0 Participants n=2 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	8 Participants n=33 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	3 Participants n=22 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.	11 Participants n=57 Participants • Number analyzed is the number of participants who experienced PD, loss of clinical benefit, or unacceptable toxicity during Stage 1 and entered Stage 2 to continue treatment with a different treatment regimen.

PRIMARY outcome

Timeframe: Up to 50.4 months

Population: Efficacy population included all participants who received at least one dose of each drug for their assigned treatment regimen. Cohort 1 with 'Atezolizumab (control arm)' was closed during the study conduct and was reactivated with 'Atezo + Tira' as a new comparator arm. Comparative statistics are not presented for Atezo + Tira arm \& Atezo + CEA-TCB arms (Cohorts 1 \& 2) due to the small sample size (N=1), which precludes any meaningful conclusion.

Outcome measures

Outcome measures
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Control (Docetaxel) n=61 Participants Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 Participants Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=15 Participants Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=16 Participants Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=30 Participants Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=40 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=36 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 Participants Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=31 Participants Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 Participants Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stage 1: Percentage of Participants With Objective Response (OR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)	33.3 percentage of participants Interval 0.84 to 90.57	13.1 percentage of participants Interval 5.84 to 24.22	0 percentage of participants Interval 0.0 to 52.18	100 percentage of participants Interval 2.5 to 100.0	0 percentage of participants Interval 0.0 to 97.5	0 percentage of participants Interval 0.0 to 21.8	0 percentage of participants Interval 0.0 to 97.5	6.7 percentage of participants Interval 0.17 to 31.95	6.3 percentage of participants Interval 0.16 to 30.23	6.7 percentage of participants Interval 0.82 to 22.07	20.0 percentage of participants Interval 9.05 to 35.65	16.7 percentage of participants Interval 6.37 to 32.81	6.7 percentage of participants Interval 0.82 to 22.07	3.2 percentage of participants Interval 0.08 to 16.7	0 percentage of participants Interval 0.0 to 36.94	—	—	—

SECONDARY outcome

Timeframe: From randomization to the first occurrence of PD or death (Up to 48.6 months)

Population: Efficacy population included all participants who received at least one dose of each drug for their assigned treatment regimen. Cohort 1 with 'Atezolizumab (control arm)' was closed during the study conduct and was reactivated with "Atezo + Tira" as a new comparator arm. Comparative statistics are not presented for Atezo + Tira arm \& Atezo + CEA-TCB arms (Cohorts 1 \& 2) due to the small sample size (N=1), which precludes any meaningful conclusion.

PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, PFS was censored at the day of the last tumor assessment. Kaplan-Meier (K-M) method was used to estimate PFS. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

Outcome measures

Outcome measures
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Control (Docetaxel) n=61 Participants Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 Participants Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=15 Participants Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=16 Participants Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=30 Participants Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=40 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=36 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 Participants Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=31 Participants Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 Participants Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stage 1: Progression-free Survival (PFS) as Determined by Investigator According to RECIST V1.1	1.51 months Interval 1.31 to Upper limit of 95% confidence interval (CI) was not estimable due to an insufficient number of participants with events.	4.83 months Interval 4.11 to 5.91	2.66 months Interval 0.69 to Upper limit of 95% CI was not estimable due to an insufficient number of participants with events.	6.90 months 95% CI was not estimable due to an insufficient number of participants with events.	1.64 months 95% CI was not estimable due to an insufficient number of participants with events.	2.43 months Interval 1.84 to 6.77	17.48 months 95% CI was not estimable due to an insufficient number of participants with events.	2.30 months Interval 1.38 to 5.52	5.09 months Interval 3.22 to 8.54	2.64 months Interval 1.71 to 3.98	6.95 months Interval 4.37 to 8.28	7.93 months Interval 4.67 to 15.67	5.49 months Interval 4.27 to 7.16	2.17 months Interval 1.48 to 4.37	3.50 months Interval 1.54 to 5.75	—	—	—

SECONDARY outcome

Timeframe: At Month 6

PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, PFS was censored at the day of the last tumor assessment. The KM approach was used to estimate the percentage of participants who were event-free for PFS at Month 6. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

Outcome measures

Outcome measures
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Control (Docetaxel) n=61 Participants Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 Participants Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=15 Participants Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=16 Participants Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=30 Participants Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=40 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=36 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 Participants Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=31 Participants Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 Participants Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stage 1: PFS Rate at Month 6	33.33 percentage of participants Interval 0.0 to 86.68	36.79 percentage of participants Interval 23.61 to 49.96	20.00 percentage of participants Interval 0.0 to 55.06	100.00 percentage of participants Interval 100.0 to 100.0	NA percentage of participants Percentage and 95% CI could not be estimated because the participant was censored prior to 6 months.	29.22 percentage of participants Interval 3.33 to 55.11	100.00 percentage of participants Interval 100.0 to 100.0	26.67 percentage of participants Interval 4.29 to 49.05	37.50 percentage of participants Interval 13.78 to 61.22	20.00 percentage of participants Interval 5.69 to 34.31	55.00 percentage of participants Interval 39.58 to 70.42	61.11 percentage of participants Interval 45.19 to 77.04	43.33 percentage of participants Interval 25.6 to 61.07	12.90 percentage of participants Interval 1.1 to 24.7	12.50 percentage of participants Interval 0.0 to 35.42	—	—	—

SECONDARY outcome

Timeframe: From randomization to death (Up to 67 months)

OS was defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. K-M method was used to estimate OS. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

Outcome measures

Outcome measures
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Control (Docetaxel) n=61 Participants Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 Participants Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=15 Participants Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=16 Participants Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=30 Participants Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=40 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=36 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 Participants Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=31 Participants Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 Participants Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stage 1: Overall Survival (OS)	2.96 months Interval 2.3 to Upper limit of 95% CI was not estimable due to an insufficient number of participants with events.	9.63 months Interval 8.34 to 14.78	32.66 months Interval 10.94 to Upper limit of 95% CI was not estimable due to an insufficient number of participants with events.	NA months Median and 95% CI were not estimable due to an insufficient number of participants with events.	3.48 months 95% CI was not estimable due to an insufficient number of participants with events.	7.75 months Interval 1.91 to 16.56	17.48 months 95% CI was not estimable due to an insufficient number of participants with events.	11.53 months Interval 2.07 to 17.22	9.40 months Interval 4.63 to 23.59	12.45 months Interval 5.59 to 15.51	13.70 months Interval 10.61 to 21.06	16.92 months Interval 9.76 to 33.71	12.48 months Interval 7.62 to 17.64	9.10 months Interval 7.82 to 14.55	NA months Interval 6.21 to Median and upper limit of 95% CI were not estimable due to an insufficient number of participants with events.	—	—	—

SECONDARY outcome

Timeframe: At Month 6

OS was defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. The Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at Month 6. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

Outcome measures

Outcome measures
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Control (Docetaxel) n=61 Participants Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 Participants Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=15 Participants Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=16 Participants Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=30 Participants Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=40 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=36 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 Participants Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=31 Participants Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 Participants Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stage 1: OS Rate at Month 6	33.33 percentage of participants Interval 0.0 to 86.68	78.34 percentage of participants Interval 67.47 to 89.2	100.00 percentage of participants Interval 100.0 to 100.0	100.00 percentage of participants Interval 100.0 to 100.0	NA percentage of participants Percentage and 95% CI could not be estimated because the participant was censored prior to 6 months.	53.85 percentage of participants Interval 26.02 to 81.67	100.00 percentage of participants Interval 100.0 to 100.0	60.00 percentage of participants Interval 35.21 to 84.79	68.18 percentage of participants Interval 45.06 to 91.3	66.92 percentage of participants Interval 49.21 to 84.64	82.50 percentage of participants Interval 70.72 to 94.28	81.82 percentage of participants Interval 68.66 to 94.98	79.62 percentage of participants Interval 65.04 to 94.19	75.62 percentage of participants Interval 59.87 to 91.37	87.50 percentage of participants Interval 64.58 to 100.0	—	—	—

SECONDARY outcome

Timeframe: From first occurrence of a documented OR until the time of documented PD or death (Up to 50.4 months)

Population: Efficacy population=all participants who received at least 1 dose of each drug for their assigned treatment regimen. Overall number analyzed=all participants who achieved OR. Cohort 1 with 'Atezolizumab (control arm)' was closed during the study conduct \& was reactivated with 'Atezo + Tira' as a new comparator arm. Comparative statistics are not presented for Atezo + Tira arm \& Atezo + CEA-TCB arms (Cohorts 1 \& 2) due to the small sample size (N=1), which precludes any meaningful conclusion.

DOR was defined as the time from the first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurred first as per investigator assessment using RECIST v1.1. DOR was calculated for participants who had a best confirmed OR of CR/PR. CR and PR were defined as outlined in the description for ORR outcome measure. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, DOR was censored at the day of the last tumor assessment. K-M method was used to estimate DOR. The participant in the 'S1C2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

Outcome measures

Outcome measures
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=1 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Control (Docetaxel) n=8 Participants Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=1 Participants Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=1 Participants Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=2 Participants Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=8 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=6 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=2 Participants Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=1 Participants Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST V1.1	30.39 months 95% CI was not estimable due to an insufficient number of participants with events.	7.03 months Interval 3.48 to Upper limit of 95% CI was not estimable due to an insufficient number of participants with events.	—	5.36 months 95% CI was not estimable due to an insufficient number of participants with events.	—	—	—	19.09 months 95% CI was not estimable due to an insufficient number of participants with events.	16.20 months 95% CI was not estimable due to an insufficient number of participants with events.	4.17 months Interval 1.41 to Upper limit of 95% CI was not estimable due to an insufficient number of participants with events.	14.54 months Interval 5.13 to 16.62	20.99 months Interval 11.1 to Upper limit of 95% CI was not estimable due to an insufficient number of participants with events.	5.36 months Interval 4.17 to Upper limit of 95% CI was not estimable due to an insufficient number of participants with events.	23.26 months 95% CI was not estimable due to an insufficient number of participants with events.	—	—	—	—

SECONDARY outcome

Timeframe: Up to 50.4 months

Population: Efficacy population included all participants who received at least one dose of each drug for their assigned treatment regimen. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

DC was defined as stable disease (SD) for ≥ 12 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1 Disease control rate (DCR) was defined as the percentage of participants with DC. CR was defined as the disappearance of all target \& non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Percentages have been rounded off.

Outcome measures

Outcome measures
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Control (Docetaxel) n=61 Participants Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 Participants Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=15 Participants Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=16 Participants Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=30 Participants Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=40 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=36 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 Participants Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=31 Participants Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 Participants Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST V1.1	33.3 percentage of participants Interval 0.84 to 90.57	57.4 percentage of participants Interval 44.06 to 69.96	40.0 percentage of participants Interval 5.27 to 85.34	100 percentage of participants Interval 2.5 to 100.0	0 percentage of participants Interval 0.0 to 97.5	33.3 percentage of participants Interval 11.82 to 61.62	100 percentage of participants Interval 2.5 to 100.0	40.0 percentage of participants Interval 16.34 to 67.71	56.3 percentage of participants Interval 29.88 to 80.25	36.7 percentage of participants Interval 19.93 to 56.14	65.0 percentage of participants Interval 48.32 to 79.37	69.4 percentage of participants Interval 51.89 to 83.65	66.7 percentage of participants Interval 47.19 to 82.71	41.9 percentage of participants Interval 24.55 to 60.92	37.5 percentage of participants Interval 8.52 to 75.51	—	—	—

SECONDARY outcome

Timeframe: From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months)

Population: Safety-evaluable population included all participants who received any amount of study treatment. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses.

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. SAEs = Serious AEs; AESIs = Adverse Events of Special Interest.

Outcome measures

Outcome measures
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Control (Docetaxel) n=61 Participants Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 Participants Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 Participants Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 Participants Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=15 Participants Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=16 Participants Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=30 Participants Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=40 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=43 Participants Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 Participants Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=31 Participants Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 Participants Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab n=2 Participants Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab n=32 Participants Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin n=20 Participants Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Stages 1 and 2: Number of Participants With Adverse Events (AEs)	3 Participants	60 Participants	5 Participants	1 Participants	1 Participants	15 Participants	1 Participants	15 Participants	16 Participants	30 Participants	38 Participants	42 Participants	30 Participants	30 Participants	8 Participants	2 Participants	31 Participants	19 Participants

Adverse Events

Stage 1 Cohort 1: Control (Atezolizumab)

Serious events: 2 serious events

Other events: 3 other events

Deaths: 3 deaths

Stage 1 Cohort 1: Atezolizumab + Cobimetinib

Serious events: 4 serious events

Other events: 5 other events

Deaths: 3 deaths

Stage 1 Cohort 1: Atezolizumab + CEA-TCB

Serious events: 1 serious events

Other events: 1 other events

Deaths: 0 deaths

Stage 1 Cohort 1: Atezolizumab + Tiragolumab

Serious events: 1 serious events

Other events: 1 other events

Deaths: 1 deaths

Stage 1 Cohort 2: Control (Docetaxel)

Serious events: 20 serious events

Other events: 58 other events

Deaths: 36 deaths

Stage 1 Cohort 2: Atezolizumab + Cobimetinib

Serious events: 8 serious events

Other events: 13 other events

Deaths: 10 deaths

Stage 1 Cohort 2: Atezolizumab + CEA-TCB

Serious events: 1 serious events

Other events: 1 other events

Deaths: 1 deaths

Stage 1 Cohort 2: Atezolizumab + CPI-444

Serious events: 8 serious events

Other events: 14 other events

Deaths: 10 deaths

Stage 1 Cohort 2: Docetaxel + Atezolizumab

Serious events: 5 serious events

Other events: 16 other events

Deaths: 10 deaths

Stage 1 Cohort 2: Atezolizumab + Ipatasertib

Serious events: 13 serious events

Other events: 30 other events

Deaths: 14 deaths

Stage 1 Cohort 2: Atezolizumab + Bevacizumab

Serious events: 13 serious events

Other events: 36 other events

Deaths: 22 deaths

Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy

Serious events: 17 serious events

Other events: 41 other events

Deaths: 23 deaths

Stage 1 Cohort 2: Atezolizumab + SG

Serious events: 14 serious events

Other events: 30 other events

Deaths: 19 deaths

Stage 1 Cohort 2: Atezolizumab + Evolocumab

Serious events: 10 serious events

Other events: 29 other events

Deaths: 25 deaths

Stage 1 Cohort 2: Atezolizumab + Camonsertib

Serious events: 4 serious events

Other events: 8 other events

Deaths: 4 deaths

Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab

Serious events: 1 serious events

Other events: 2 other events

Deaths: 0 deaths

Stage 2 Cohort 2: Docetaxel + Atezolizumab

Serious events: 13 serious events

Other events: 30 other events

Deaths: 29 deaths

Stage 2 Cohort 2: Atezolizumab + Linagliptin

Serious events: 6 serious events

Other events: 18 other events

Deaths: 19 deaths

Serious adverse events

Serious adverse events
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 participants at risk Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 participants at risk Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 participants at risk Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 participants at risk Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Control (Docetaxel) n=61 participants at risk Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 participants at risk Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 participants at risk Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=15 participants at risk Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=16 participants at risk Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=30 participants at risk Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=40 participants at risk Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=43 participants at risk Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 participants at risk Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=31 participants at risk Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 participants at risk Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab n=2 participants at risk Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab n=32 participants at risk Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin n=20 participants at risk Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
General disorders Pyrexia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Hepatobiliary disorders Cholecystitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Hepatobiliary disorders Gallbladder rupture	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Immune system disorders Cytokine release syndrome	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Abdominal infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Arthritis infective	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations COVID-19	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations COVID-19 pneumonia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Cellulitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Encephalitis herpes	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Enterocolitis infectious	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Influenza	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Large intestine infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Lower respiratory tract infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Neutropenic sepsis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Osteomyelitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Pneumonia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.8% 6/61 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Pneumonia aspiration	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Respiratory tract infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Sepsis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Septic shock	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Skin infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Upper respiratory tract infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Urinary tract infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Urosepsis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Viral upper respiratory tract infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Accidental overdose	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Femur fracture	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Procedural pneumothorax	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Radiation necrosis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Wound dehiscence	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Blood creatinine increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Lipase increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Platelet count decreased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Transaminases increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Malnutrition	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour associated fever	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Cauda equina syndrome	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Cerebral infarction	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Dizziness	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Embolic cerebral infarction	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Encephalitis autoimmune	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Hepatic encephalopathy	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Spinal cord compression	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Syncope	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Psychiatric disorders Completed suicide	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Acute kidney injury	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Nephritis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Renal failure	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Renal tubular necrosis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Bronchial fistula	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Bronchospasm	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Immune-mediated lung disease	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Blister	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Capillary leak syndrome	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Deep vein thrombosis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Embolism	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Hypotension	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Lymphoedema	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Superior vena cava syndrome	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Anaemia	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Cardiac disorders Acute myocardial infarction	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Cardiac disorders Atrial fibrillation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Cardiac disorders Atrial flutter	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Cardiac disorders Atrial tachycardia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Cardiac disorders Cardiac failure	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Cardiac disorders Cardiogenic shock	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Endocrine disorders Adrenal insufficiency	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Retinal vein occlusion	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Serous retinal detachment	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Colitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Constipation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Diarrhoea	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Dysphagia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Enteritis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Gastric perforation	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Gastric ulcer	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Gastritis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Gastrointestinal obstruction	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Ileus paralytic	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Intestinal perforation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Vomiting	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Asthenia	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Death	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Fatigue	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders General physical health deterioration	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Implant site haematoma	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Oedema peripheral	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.

Other adverse events

Other adverse events
Measure	Stage 1 Cohort 1: Control (Atezolizumab) n=3 participants at risk Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Cobimetinib n=5 participants at risk Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + CEA-TCB n=1 participants at risk Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 1: Atezolizumab + Tiragolumab n=1 participants at risk Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.	Stage 1 Cohort 2: Control (Docetaxel) n=61 participants at risk Participants received docetaxel 75 mg/m\^2, IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Cobimetinib n=15 participants at risk Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CEA-TCB n=1 participants at risk Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + CPI-444 n=15 participants at risk Participants received CPI-444 100 mg, PO, BID, on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Docetaxel + Atezolizumab n=16 participants at risk Participants received docetaxel 75 mg/m\^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Ipatasertib n=30 participants at risk Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab n=40 participants at risk Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy n=43 participants at risk Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + SG n=30 participants at risk Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Evolocumab n=31 participants at risk Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 1 Cohort 2: Atezolizumab + Camonsertib n=8 participants at risk Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.	Stage 2 Cohort 1: Carboplatin + Pemetrexed + Atezolizumab n=2 participants at risk Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m\^2, IV infusions on Day 1 of each cycle and carboplatin AUC 6 mg/mL/min (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Docetaxel + Atezolizumab n=32 participants at risk Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m\^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.	Stage 2 Cohort 2: Atezolizumab + Linagliptin n=20 participants at risk Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.
Gastrointestinal disorders Diarrhoea	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	32.8% 20/61 • Number of events 27 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	46.7% 7/15 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	37.5% 6/16 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	63.3% 19/30 • Number of events 42 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	22.5% 9/40 • Number of events 13 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.9% 9/43 • Number of events 12 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	43.3% 13/30 • Number of events 18 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	22.6% 7/31 • Number of events 11 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 2/8 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 8/32 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 2/20 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Dry mouth	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 2/20 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Dyspepsia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Dysphagia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Haemorrhoids	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Intestinal dilatation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Lip dry	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Mouth haemorrhage	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Mouth ulceration	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Nausea	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	19.7% 12/61 • Number of events 14 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	26.7% 4/15 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 4/16 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	33.3% 10/30 • Number of events 10 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.5% 3/40 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 12/30 • Number of events 17 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 4/8 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 3/20 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Stomatitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	8.2% 5/61 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.4% 3/32 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Toothache	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Vomiting	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 4/16 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	26.7% 8/30 • Number of events 10 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 6/30 • Number of events 13 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Administration site extravasation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Asthenia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	39.3% 24/61 • Number of events 33 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	31.2% 5/16 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	36.7% 11/30 • Number of events 19 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 5/40 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	39.5% 17/43 • Number of events 20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	26.7% 8/30 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 2/8 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	43.8% 14/32 • Number of events 21 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Chest pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Chills	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Fatigue	66.7% 2/3 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.0% 11/61 • Number of events 13 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 4/16 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	17.5% 7/40 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	11.6% 5/43 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	23.3% 7/30 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 2/8 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 2/20 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Gait disturbance	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Infusion site pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Localised oedema	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Mucosal dryness	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Mucosal inflammation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.6% 4/61 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	23.3% 7/30 • Number of events 10 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 6/32 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Non-cardiac chest pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Oedema peripheral	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	14.8% 9/61 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.4% 3/32 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 3/20 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Peripheral swelling	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Pyrexia	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.8% 6/61 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 6/30 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 5/40 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 6/30 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 3/20 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Swelling	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
General disorders Swelling face	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Hepatobiliary disorders Biliary obstruction	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Hepatobiliary disorders Cholecystitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Hepatobiliary disorders Hepatic pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Immune system disorders Seasonal allergy	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Abscess limb	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Arthritis bacterial	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Bronchitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations COVID-19	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.5% 3/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Conjunctivitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Escherichia infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Folliculitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Furuncle	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Gastrointestinal viral infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Gingivitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Herpes zoster	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Lower respiratory tract infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 2/20 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Nasopharyngitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Oral candidiasis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Anaemia	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	34.4% 21/61 • Number of events 23 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	26.7% 4/15 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	33.3% 5/15 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	31.2% 5/16 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	23.3% 7/30 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	11.6% 5/43 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	46.7% 14/30 • Number of events 28 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	19.4% 6/31 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	87.5% 7/8 • Number of events 14 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 2/2 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	31.2% 10/32 • Number of events 27 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 3/20 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Hyperleukocytosis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Leukopenia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 5/40 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	23.3% 10/43 • Number of events 14 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.4% 3/32 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Monocytosis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	8.2% 5/61 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	30.0% 9/30 • Number of events 32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 6/32 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.5% 3/40 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Cardiac disorders Atrial fibrillation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Cardiac disorders Atrial flutter	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Ear and labyrinth disorders Hypoacusis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Ear and labyrinth disorders Tinnitus	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Ear and labyrinth disorders Vertigo	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Endocrine disorders Hyperthyroidism	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Endocrine disorders Hypothyroidism	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Blepharitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Cataract	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Central serous chorioretinopathy	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Diplopia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Dry eye	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Eyelid oedema	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Lacrimation increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.8% 6/61 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Macular thickening	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Ocular hyperaemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Photopsia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Vision blurred	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Eye disorders Visual acuity reduced	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Abdominal distension	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	11.5% 7/61 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	22.5% 9/40 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	14.0% 6/43 • Number of events 12 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	14.0% 6/43 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Chapped lips	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Cheilitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Gastrointestinal disorders Constipation	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 6/40 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	14.0% 6/43 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	36.7% 11/30 • Number of events 14 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	19.4% 6/31 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 2/8 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 2/2 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 4/20 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Otitis media	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Pneumonia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 2/8 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Pneumonia cytomegaloviral	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Rash pustular	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Respiratory tract infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.4% 3/32 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Rhinitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Skin candida	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Upper respiratory tract infection	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Infections and infestations Urinary tract infection	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Fall	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Inappropriate schedule of product administration	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Medication error	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Radiation pneumonitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Alanine aminotransferase increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	26.7% 4/15 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.5% 3/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	16.7% 5/30 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	16.1% 5/31 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Amylase increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 5/40 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 11 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Aspartate aminotransferase increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	60.0% 3/5 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.6% 4/61 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	26.7% 4/15 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	22.5% 9/40 • Number of events 10 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	16.3% 7/43 • Number of events 10 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Blood alkaline phosphatase increased	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 5/40 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Blood creatine phosphokinase increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Blood creatinine increased	33.3% 1/3 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 6/40 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	14.0% 6/43 • Number of events 10 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Blood glucose increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Blood lactate dehydrogenase increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Blood thyroid stimulating hormone decreased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Blood thyroid stimulating hormone increased	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Body temperature increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations C-reactive protein increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Ejection fraction decreased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Electrocardiogram QT prolonged	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Gamma-glutamyltransferase increased	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 6/40 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Haemoglobin decreased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Intraocular pressure increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Lipase increased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 6/40 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 11 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Neutrophil count decreased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.6% 4/61 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 6/30 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Platelet count decreased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations Weight decreased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.5% 3/40 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Investigations White blood cell count decreased	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Decreased appetite	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	19.7% 12/61 • Number of events 17 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	43.8% 7/16 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	22.5% 9/40 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	16.3% 7/43 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 6/30 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.7% 3/31 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	37.5% 3/8 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	21.9% 7/32 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 3/20 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.5% 3/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hyperkalaemia	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.5% 3/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypoalbuminaemia	66.7% 2/3 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.8% 6/61 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 4/40 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	11.6% 5/43 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypokalaemia	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	11.6% 5/43 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 2/20 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Metabolism and nutrition disorders Iron deficiency	33.3% 1/3 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Arthralgia	66.7% 2/3 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	8.2% 5/61 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	22.5% 9/40 • Number of events 15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	23.3% 10/43 • Number of events 24 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	16.1% 5/31 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 6/32 • Number of events 9 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 5/40 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	14.0% 6/43 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	26.7% 8/30 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.7% 3/31 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Clubbing	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	11.6% 5/43 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Muscle twitching	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	11.5% 7/61 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.5% 3/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.6% 8/43 • Number of events 10 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.4% 3/32 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Osteoporotic fracture	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 3/20 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Seborrhoeic keratosis	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour associated fever	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Dizziness	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.6% 4/61 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 6/40 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Dysgeusia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.6% 4/61 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.6% 5/32 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Headache	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 6/30 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 4/40 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	14.0% 6/43 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 2/20 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Hyperammonaemic encephalopathy	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Hypoaesthesia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Motor dysfunction	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Neuralgia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Neuropathy peripheral	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	14.8% 9/61 • Number of events 12 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 4/16 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 4/32 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Neurotoxicity	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.6% 4/61 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.4% 3/32 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Paraesthesia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Post herpetic neuralgia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Somnolence	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Spinal cord compression	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Syncope	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Tremor	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Nervous system disorders Vocal cord paralysis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Product Issues Device occlusion	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Psychiatric disorders Anger	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Psychiatric disorders Anxiety	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Psychiatric disorders Confusional state	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Psychiatric disorders Depression	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Psychiatric disorders Insomnia	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.6% 4/61 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.5% 3/40 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 3/20 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Dysuria	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Haematuria	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Micturition urgency	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Proteinuria	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 6/40 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	23.3% 10/43 • Number of events 11 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Renal failure	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Renal impairment	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Renal and urinary disorders Urinary hesitation	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Reproductive system and breast disorders Benign prostatic hyperplasia	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Reproductive system and breast disorders Pelvic pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Reproductive system and breast disorders Prostatomegaly	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	16.4% 10/61 • Number of events 11 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 6/30 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 6/40 • Number of events 12 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.6% 8/43 • Number of events 11 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 4/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	37.5% 3/8 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.6% 5/32 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 2/20 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 5/40 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.3% 4/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	19.7% 12/61 • Number of events 14 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 6/15 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 8/40 • Number of events 14 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	14.0% 6/43 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	23.3% 7/30 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	62.5% 5/8 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.4% 3/32 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 3/20 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 4/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Nasal dryness	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.5% 2/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	11.5% 7/61 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 4/40 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	9.7% 3/31 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Rales	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 2/61 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Respiratory, thoracic and mediastinal disorders Throat irritation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	32.8% 20/61 • Number of events 20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	37.5% 6/16 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 15/30 • Number of events 17 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	31.2% 10/32 • Number of events 11 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Dermatitis psoriasiform	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.8% 3/16 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	7.0% 3/43 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 3/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Nail discolouration	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.6% 4/61 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Nail disorder	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 2/16 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Neurodermatitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.5% 1/8 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Onycholysis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	8.2% 5/61 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 1/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.9% 3/61 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 3/15 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	13.3% 2/15 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	25.0% 4/16 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	10.0% 4/40 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	16.3% 7/43 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	36.7% 11/30 • Number of events 15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	12.9% 4/31 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 2/32 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	15.0% 3/20 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Rash	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.6% 4/61 • Number of events 5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	26.7% 4/15 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	16.7% 5/30 • Number of events 6 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 2/40 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	18.6% 8/43 • Number of events 10 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	20.0% 6/30 • Number of events 8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	50.0% 1/2 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Rash maculo-papular	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Skin atrophy	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Skin exfoliation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	100.0% 1/1 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Skin hyperpigmentation	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Skin ulcer	33.3% 1/3 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Skin and subcutaneous tissue disorders Stasis dermatitis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Deep vein thrombosis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Flushing	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 1/15 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/16 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.3% 1/43 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Hypertension	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	40.0% 2/5 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	17.5% 7/40 • Number of events 7 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	11.6% 5/43 • Number of events 13 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.3% 1/30 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Hypotension	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	2.5% 1/40 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	4.7% 2/43 • Number of events 4 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.7% 2/30 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.2% 1/31 • Number of events 2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	3.1% 1/32 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	5.0% 1/20 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Jugular vein thrombosis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	1.6% 1/61 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.
Vascular disorders Thrombosis	0.00% 0/3 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/5 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/61 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/15 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	6.2% 1/16 • Number of events 1 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/40 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/43 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/30 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/31 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/8 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/2 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/32 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.	0.00% 0/20 • From baseline until 30 days (for AEs) or 135 days (for SAEs & AESIs) after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurred first (Stage 1: up to 54.8 months; Stage 2: up to 43.1 months) All-cause mortality: Stage 1: Up to approximately 67 months; Stage 2: Up to approximately 45.8 months AEs, SAEs and AESIs: Safety-evaluable population included all participants who received any amount of study treatment. All-cause Mortality: Randomized population included all participants randomized to each treatment arm. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the safety analyses. No mortality data could be collected for this arm as the participant withdrew from the study before receiving treatment.

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 800 821-8590

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER